NCT03398356View on ClinicalTrials.gov

Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.

PHASE4CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

December 30, 2018

Study Completion Date

April 30, 2019

Conditions
PreDiabetesImpaired Fasting Glucose (IFG)Impaired Glucose Tolerance (IGT)
Interventions
DRUG

Metformin

"for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg~for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg."

Trial Locations (1)

54-438

NZOZ Nowy Dwór, Wroclaw

All Listed Sponsors
lead

Wroclaw Medical University

OTHER

NCT03398356 - Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients. | Biotech Hunter | Biotech Hunter